Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Accuray Inc (ARAY)

Accuray Inc (ARAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 470,061
  • Shares Outstanding, K 91,274
  • Annual Sales, $ 382,930 K
  • Annual Income, $ 3,830 K
  • 60-Month Beta 2.06
  • Price/Sales 1.21
  • Price/Cash Flow 255.03
  • Price/Book 6.91
Trade ARAY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.01
  • Number of Estimates 3
  • High Estimate 0.03
  • Low Estimate -0.06
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.96 +31.06%
on 12/28/20
5.42 -4.24%
on 01/27/21
+0.76 (+17.16%)
since 12/24/20
3-Month
2.77 +87.36%
on 10/29/20
5.42 -4.24%
on 01/27/21
+2.19 (+73.00%)
since 10/27/20
52-Week
1.33 +290.23%
on 03/25/20
5.42 -4.24%
on 01/27/21
+1.42 (+37.67%)
since 01/27/20

Most Recent Stories

More News
Accuray (ARAY) Beats Q2 Earnings and Revenue Estimates

Accuray (ARAY) delivered earnings and revenue surprises of 600.00% and 4.96%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

ARAY : 5.19 (+0.78%)
Accuray: Fiscal 2Q Earnings Snapshot

SUNNYVALE, Calif. (AP) _ Accuray Inc. (ARAY) on Wednesday reported fiscal second-quarter net income of $4.8 million.

ARAY : 5.19 (+0.78%)
Accuray Reports Second Quarter Fiscal 2021 Financial Results

, /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the second quarter of fiscal 2021 ended .

ARAY : 5.19 (+0.78%)
Accuray, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / January 27, 2021 / Accuray, Inc. (NASDAQ:ARAY) will be discussing their earnings results in their 2021 Second Quarter Earnings call to be held on January 27, 2021 at 4:30 PM...

ARAY : 5.19 (+0.78%)
Accuray (ARAY) Releases Encouraging Breast Cancer Study Results

Accuray (ARAY) releases positive data from a prospective trial of 338 women with low-risk breast cancer.

MDT : 111.50 (-4.50%)
ARAY : 5.19 (+0.78%)
LH : 214.81 (-3.23%)
PACB : 31.06 (-5.54%)
Radiation Oncology Market Research 2020-2024 - Featuring Accuray Inc., Becton, Dickinson and Co., Canon Inc., Among Others to Contribute to the Market Growth | Technavio

The radiation oncology market is poised to grow by $ 1.70 bn during 2020-2024, progressing at a CAGR of almost 5% during the forecast period.

ARAY : 5.19 (+0.78%)
CAJ : 23.80 (+6.20%)
Seven-year Data Shows Accuray TomoTherapy® System Provides Excellent Long-Term Control of Low-Risk Breast Cancer

, /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control...

ARAY : 5.19 (+0.78%)
Accuray to Report Second Quarter Fiscal 2021 Financial Results on January 27, 2021

, /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2021, ended December 31, 2020, after the market close on Wednesday January...

ARAY : 5.19 (+0.78%)
Accuray (ARAY) Gets 510(k) Nod for ClearRT in TomoTherapy

Accuray (ARAY) new innovative imaging solution is designed to provide cost effective and exceptional diagnostic quality image.

ARAY : 5.19 (+0.78%)
CMD : 79.99 (-0.66%)
Accuray To Participate at J.P. Morgan's 39th Annual Healthcare Conference

, /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced its participation in the 39 J.P. Morgan Annual Healthcare Conference. , President and CEO, is scheduled to present on at PACIFIC...

JPM : 127.86 (-2.83%)
ARAY : 5.19 (+0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ACCURAY INCORPORATED based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends...

See More

Key Turning Points

3rd Resistance Point 5.89
2nd Resistance Point 5.66
1st Resistance Point 5.42
Last Price 5.19
1st Support Level 4.95
2nd Support Level 4.72
3rd Support Level 4.48

See More

52-Week High 5.42
Last Price 5.19
Fibonacci 61.8% 3.86
Fibonacci 50% 3.38
Fibonacci 38.2% 2.89
52-Week Low 1.33

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar